Results 81 to 90 of about 8,272 (178)

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

Autonomic Nervous System Phenotyping Across Chronic Demyelinating Peripheral Neuropathies: A Comparative Study

Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Background and Aims This study aimed to systematically phenotype autonomic nervous system (ANS) involvement in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), monoclonal gammopathy of undetermined significance‐associated neuropathy (MGUS‐PNP), Charcot–Marie–Tooth disease Type 1A (CMT1A), and hereditary neuropathy with ...
Bogdan Bjelica, Teodora Todorovic, Ivo Bozovic, Aleksa Palibrk, Vladimir Jankovic, Ivana Basta, Stojan Peric   +6 more
wiley   +1 more source

Glomerular Capillary Microaneurysms in Membranoproliferative Glomerulonephritis: A Clinicopathological Study Highlighting the Involvement of IgG3

Pathology International, Volume 76, Issue 6, June 2026.
Glomerular capillary microaneurysms (GCMs) were most frequently observed in proliferative glomerulonephritis with monoclonal immunoglobulin G deposits (PGNMID) among MPGN‐pattern glomerular diseases, but were not restricted to this entity. These lesions were characterized by exclusive IgG3‐dominant glomerular deposition, irrespective of light‐chain ...
Akiko Mii, Tomohiro Kaneko, Momoko Arai, Takehisa Yamada, Mayuko Takeuchi, Tetsuya Kashiwagi, Naomi Kuwahara, Arimi Ishikawa, Ryuji Ohashi, Yukinao Sakai, Masato Iwabu, Akira Shimizu   +11 more
wiley   +1 more source

A patient with AL amyloidosis presenting with refractory tuberculosis, chest tightness and hypotension: case report

BMC Pulmonary Medicine
Introduction Immunoglobulin light chain (AL) amyloidosis presents a clinical spectrum characterized by diverse manifestations and involvement of multiple organs, posing a significant diagnostic challenge for physicians.
Jun Yang, Mohamed Fahim Fathima Farhath, Huohuan Tian, Linhui Yang, Dan Liu   +4 more
doaj   +1 more source

Detection of vascular amyloid deposits in a bone marrow aspirate

British Journal of Haematology, Volume 208, Issue 6, Page 1907-1908, June 2026.
Konstantinos Liapis, Georgios Kanellis, Georgios Vrachiolias, Evangelia Charitaki   +3 more
wiley   +1 more source

野生型转甲状腺素蛋白心脏淀粉样变性病例1例

Zhongguo shiyan zhenduanxue, 2023
转甲状腺素蛋白心脏淀粉样变(transthyretin cardiac amyloidosis, ATTR-CA)是除外免疫球蛋白轻链心脏淀粉样变(immunoglobulin light chain amyloidosis, AL-CA)最常见的心脏淀粉样变(cardiac amyloidosis, CA)[1]。ATTR-CA患者生活质量差、生存率低[2]。
翟书慧, 王丹, 赵绮旎, 刘龙
doaj  

Cardiac amyloidosis

Annales Academiae Medicae Silesiensis
Amyloidosis is a rare disease characterized by an abnormal accumulation of the amyloid protein in tissues. Amyloidosis can be divided into two main subtypes: transthyretin amyloidosis (ATTR-CA) and immunoglobulin light chain amyloidosis (AL-CA ...
Magdalena Balwierz, Bartosz Gruchlik, Katarzyna Mizia-Stec   +2 more
doaj   +1 more source

Refractory IgM AL amyloidosis with massive soft tissue tumors: Rescue with zanubrutinib. A case report

Current Problems in Cancer: Case Reports
Waldenström macroglobulinemia (WM) is a rare indolent B-cell non-Hodgkin lymphoma with lymphoplasmacytic morphology, associated with immunoglobulin M (IgM) monoclonal gammopathy. The coexistence of WM and immunoglobulin light chain (AL) amyloidosis is an
Piotr Jachimowski, Łukasz Ciulkiewicz, Mateusz Ziarkiewicz, Bogna Ziarkiewicz-Wróblewska, Marta Legatowicz-Koprowska, Krzysztof Jamroziak   +5 more
doaj   +1 more source

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. [PDF]

Blood Cancer J, 2023
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A.   +5 more
europepmc   +1 more source

Concurrent Therapy for Immunoglobulin Light Chain Cardiac Amyloidosis and Transthyretin Cardiac Amyloidosis

Internal Medicine
Cardiac amyloidosis (CA), predominantly caused by amyloid transthyretin (ATTR) or immunoglobulin light chain (AL), has a poor prognosis, and a precise diagnosis is crucial because the optimal treatments differ between the two conditions. However, diagnosing AL-CA is challenging because of the unavailability of effective AL-detecting antibodies ...
Horigome, Yuichi, Ishii, Shunsuke, Matsumoto, Manabu, Ikeda, Yoshihiko, Hatakeyama, Kinta, Ako, Junya, Suzuki, Takahiro   +6 more
openaire   +3 more sources